Genome (DNA) Sequencing Market Size, Share & Industry | 2030
Genome (DNA) Sequencing Market Size, Share & Industry | 2030
Segments - Global Genome (DNA) Sequencing Market by Technology (Next-Generation Sequencing, Third Generation DNA Sequencing, Microarray, Non-Sanger’s Sequencing, Sanger Sequencing, and Polymerase Chain Reaction), Applications (Research, Diagnostic, and Others), Types (Services and Products), End-users (Research Institutes, Pharmaceutical & Biotechnological Companies, and Healthcare Facilities & Diagnostic Centres), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
Upcoming
| Report ID :HC-4008
| 4.1 Rating
| 78 Reviews
| 165 Pages
| Format :
Report Description
The global genome (DNA) sequencing market size was valued at USD 4.9 billion in 2020 and is estimated to expand at a CAGR of 11.5% during the forecast period, 2021–2028. The growth of the market is attributed to rapid advances in sequencing technology and analytics.
Genome (DNA) sequencing is a method that allows several DNA strands to be sequenced simultaneously. Genome sequencing technology aids in the sequencing of an organism's whole genome in order to determine the order or sequence of DNA nucleotides or bases coded with letters including As, Gs, Cs, and Ts. Genome sequencing methods made it feasible to investigate genetics, biomarkers, forensics, customized medicine, and other fields. This technology aids in the transition from traditional procedures to customized medications with the use of genetics. It is a widely utilized method for whole-genome sequencing. In March 2021, Sysmex Corporation introduced the XR-Series automated haematology analyzer, a next-generation flagship model in the haematology industry, and the XQ-Series automated haematology analyzer, a small 3-part WBC differential model.
The COVID-19 pandemic had a positive influence on the market, as it increased the demand for DNA sequencing technology in the development of treatments and diagnostics. For example, the FDA approved the Helix COVID-19 NGS test in August 2020 under an Emergency Use Authorization (EUA) for use only by Helix Laboratory. It is an amplicon-based next-generation sequencing (NGS) test for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens from people suspected of COVID-19. As a result of the expanding DNA sequencing-based research and development efforts in the development of COVID-19 diagnostic tools or effective therapies, the market is expected to continue to expand at a substantial rate throughout the forecast period.
Market Trends, Drivers, Restraints, and Opportunities
- Declining cost of genetic sequencing and data integration is expected to drive the market during the forecast period.
- Increasing penetration rate of companion diagnostics and personalized medicine boost the market.
- Rising incidence of cancer and genetic disorders are anticipated to propel the market.
- Legal and ethical limitations of DNA sequencing hinder the market expansion.
- Limitations associated with DNA sequencing are estimated to hamper the growth of the market in the coming years.
- Sequencing poses production and bioinformatics issues, which restrain the market growth.
- Investments and funding in DNA sequencing, and the arrival of single-cell sequencing creates lucrative opportunities for the market players.
Scope of the Report
The report on the global genome (DNA) sequencing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Global Genome (DNA) Sequencing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Technology (Next-Generation Sequencing, Third Generation DNA Sequencing, Microarray, Non-Sanger’s Sequencing, Sanger Sequencing, and Polymerase Chain Reaction), Applications (Research, Diagnostic, and Others), Types (Services and Products), and End-users (Research Institutes, Pharmaceutical & Biotechnological Companies, and Healthcare Facilities & Diagnostic Centres) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Genome Electric Company; Agilent Technologies Inc.; Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Illumina Inc.; BGI; IntegraGen; Bio-Rad Laboratories; QIAGEN; Danaher; Pacific Biosciences of California Inc.; and Oxford Nanopore Technologies |
Market Segment Insights
Next-Generation Sequencing segment to expand at a considerable CAGR
On the basis of technology, the genome (DNA) sequencing market is segmented into next-generation sequencing, third generation DNA sequencing, microarray, non-sanger’s sequencing, sanger sequencing, and polymerase chain reaction. The Next-Generation Sequencing (NGS) segment is projected to expand at a considerable CAGR during the forecast period, due to radical advances in technology with the declining cost of sequencing. Furthermore, NGS technology is gaining traction as a routine clinical diagnostic test, particularly in light of the COVID-19 pandemic, which boosts the segment. The third generation DNA sequencing segment is anticipated to account for a major market share during the forecast period. This approach solves the drawbacks of second-generation procedures by allowing for simple sample preparation without the requirement of quick PCR amplification. It also provides lengthy reads in hundreds of kilobase range for the discovery of repeated spots in complicated genomes.
Diagnostic segment to hold a significant share of the market
In terms of applications, the market is divided into research, diagnostic, and others. The diagnostic segment is expected to hold a significant share of the market in the coming years. Genome (DNA) sequencing has varied applications in clinical research and the development of cancer diagnostics and treatments. Doctors and businesses understand the importance of these technologies in companion diagnostics and precision medicine. The research segment accounts for a significant market share, owing to high availability of funding and investments in the field of DNA sequencing.
Services segment to expand at a high rate during the forecast period
Based on types, the genome (DNA) sequencing market is segregated into services and products. Several sequencing problems, such as unequal base distributions and numerous hairpin loops, are solved by sequencing services. The services segment is expected to expand at a high rate during the forecast period. Service providers have patented reagents and efficient technological platforms that provide accurate results, along with highly experienced personnel support with client-specific requests. The products segment is expected to be a rapidly-growing segment during the forecast period, due to ongoing release of reagents and kits to make WGS accessible and inexpensive. For example, Illumina Inc. released the NovaSeq 6000 v1.5 Reagent Kit in August 2020, which made WGS technology cost-effective and accessible to all laboratories, lowering the cost of sequencing a human genome to USD 600.
Research Institutes segment to dominate the market
On the basis of end-users, the market is fragmented into research institutes, pharmaceutical & biotechnological companies, and healthcare facilities & diagnostic centres. The research institutes segment is expected to dominate the market in the forecast period, owing to the widespread use of next-generation sequencing and sanger technology in academic and institutional research. The healthcare facilities & diagnostic centres segment is expected to grow rapidly, due to increasing application of genome (DNA) sequencing in clinical diagnosis and drug discovery.
North America is anticipated to constitute a key market share
In terms of regions, the genome (DNA) sequencing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the forecast period, owing to high investments in R&D and continuous technological developments by key players. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to presence of a large customer base in the region. For example, GenapSys, a California-based company, secured USD 75 million in February 2020 to fund its tabletop DNA sequencer to promote coronavirus management.
Segments
Segments Covered in the ReportThe global genome (DNA) sequencing market has been segmented on the basis of
Technology
- Next-Generation Sequencing
- Third Generation DNA Sequencing
- Microarray
- Non-Sanger’s Sequencing
- Sanger Sequencing
- Polymerase Chain Reaction
- Research
- Diagnostic
- Others
- Services
- Products
- Research Institutes
- Pharmaceutical & Biotechnological Companies
- Healthcare Facilities & Diagnostic Centres
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Genome Electric Company
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Illumina Inc.
- BGI
- IntegraGen
- Bio-Rad Laboratories
- QIAGEN
- Danaher
- Pacific Biosciences of California Inc.
- Oxford Nanopore Technologies
Competitive Landscape
Key players competing in the global genome (DNA) sequencing market are Genome Electric Company; Agilent Technologies Inc.; Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Illumina Inc.; BGI; IntegraGen; Bio-Rad Laboratories; QIAGEN; Danaher; Pacific Biosciences of California Inc.; and Oxford Nanopore Technologies.
The genome (DNA) sequencing market is fiercely competitive, with the presence of few large competitors. These businesses are attempting to meet expanding customer demand by investing heavily in distribution, manufacture, and comprehensive quality control in order to expand their product lines. QIAGEN and Japan's Sysmex Corporation established a global strategic agreement in July 2021 for the progress and promotion of cancer companion diagnostics, leveraging both QIAGEN's expertise in this sector and Sysmex's Plasma-Safe-SeqS technology for next-generation sequencing.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Genome (DNA) Sequencing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Genome (DNA) Sequencing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Genome (DNA) Sequencing Market - Supply Chain
4.5. Global Genome (DNA) Sequencing Market Forecast
4.5.1. Genome (DNA) Sequencing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Genome (DNA) Sequencing Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Genome (DNA) Sequencing Market Absolute $ Opportunity
5. Global Genome (DNA) Sequencing Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Genome (DNA) Sequencing Market Size and Volume Forecast by Types
5.3.1. Services
5.3.2. Products
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Genome (DNA) Sequencing Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Genome (DNA) Sequencing Market Size and Volume Forecast by Applications
6.3.1. Research
6.3.2. Diagnostic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Genome (DNA) Sequencing Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Genome (DNA) Sequencing Market Size and Volume Forecast by End Users
7.3.1. Research Institutes
7.3.2. Pharmaceutical & Biotechnological Companies
7.3.3. Healthcare Facilities & Diagnostic Centres
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Genome (DNA) Sequencing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Genome (DNA) Sequencing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Genome (DNA) Sequencing Demand Share Forecast, 2019-2026
9. North America Genome (DNA) Sequencing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Genome (DNA) Sequencing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Genome (DNA) Sequencing Market Size and Volume Forecast by Types
9.4.1. Services
9.4.2. Products
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Genome (DNA) Sequencing Market Size and Volume Forecast by Applications
9.7.1. Research
9.7.2. Diagnostic
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Genome (DNA) Sequencing Market Size and Volume Forecast by End Users
9.10.1. Research Institutes
9.10.2. Pharmaceutical & Biotechnological Companies
9.10.3. Healthcare Facilities & Diagnostic Centres
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Genome (DNA) Sequencing Demand Share Forecast, 2019-2026
10. Latin America Genome (DNA) Sequencing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Genome (DNA) Sequencing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Genome (DNA) Sequencing Market Size and Volume Forecast by Types
10.4.1. Services
10.4.2. Products
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Genome (DNA) Sequencing Market Size and Volume Forecast by Applications
10.7.1. Research
10.7.2. Diagnostic
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Genome (DNA) Sequencing Market Size and Volume Forecast by End Users
10.10.1. Research Institutes
10.10.2. Pharmaceutical & Biotechnological Companies
10.10.3. Healthcare Facilities & Diagnostic Centres
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Genome (DNA) Sequencing Demand Share Forecast, 2019-2026
11. Europe Genome (DNA) Sequencing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Genome (DNA) Sequencing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Genome (DNA) Sequencing Market Size and Volume Forecast by Types
11.4.1. Services
11.4.2. Products
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Genome (DNA) Sequencing Market Size and Volume Forecast by Applications
11.7.1. Research
11.7.2. Diagnostic
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Genome (DNA) Sequencing Market Size and Volume Forecast by End Users
11.10.1. Research Institutes
11.10.2. Pharmaceutical & Biotechnological Companies
11.10.3. Healthcare Facilities & Diagnostic Centres
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Genome (DNA) Sequencing Demand Share Forecast, 2019-2026
12. Asia Pacific Genome (DNA) Sequencing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Genome (DNA) Sequencing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Genome (DNA) Sequencing Market Size and Volume Forecast by Types
12.4.1. Services
12.4.2. Products
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Genome (DNA) Sequencing Market Size and Volume Forecast by Applications
12.7.1. Research
12.7.2. Diagnostic
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Genome (DNA) Sequencing Market Size and Volume Forecast by End Users
12.10.1. Research Institutes
12.10.2. Pharmaceutical & Biotechnological Companies
12.10.3. Healthcare Facilities & Diagnostic Centres
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Genome (DNA) Sequencing Demand Share Forecast, 2019-2026
13. Middle East & Africa Genome (DNA) Sequencing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Genome (DNA) Sequencing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Genome (DNA) Sequencing Market Size and Volume Forecast by Types
13.4.1. Services
13.4.2. Products
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Genome (DNA) Sequencing Market Size and Volume Forecast by Applications
13.7.1. Research
13.7.2. Diagnostic
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Genome (DNA) Sequencing Market Size and Volume Forecast by End Users
13.10.1. Research Institutes
13.10.2. Pharmaceutical & Biotechnological Companies
13.10.3. Healthcare Facilities & Diagnostic Centres
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Genome (DNA) Sequencing Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Genome (DNA) Sequencing Market: Market Share Analysis
14.2. Genome (DNA) Sequencing Distributors and Customers
14.3. Genome (DNA) Sequencing Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. Genome Electric Company
14.4.2. Agilent Technologies Inc.
14.4.3. Thermo Fisher Scientific Inc.
14.4.4. F. Hoffmann-La Roche Ltd.
14.4.5. Illumina Inc.
14.4.6. BGI
14.4.7. IntegraGen
14.4.8. Bio-Rad Laboratories&a
Methodology
Related Reports
Some other reports from this category!
Our Clients
